Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period

被引:95
作者
Testa, D
Lovati, R
Ferrarini, M
Salmoiraghi, F
Filippini, G
机构
[1] Ist Nazl Neurol Carlo Besta, Dept Neurol, IT-20133 Milan, Italy
[2] Ist Nazl Neurol Carlo Besta, Dept Neuroepidemiol, IT-20133 Milan, Italy
来源
AMYOTROPHIC LATERAL SCLEROSIS | 2004年 / 5卷 / 04期
关键词
amyotrophic lateral sclerosis; epidemiology; mortality; survival predictors;
D O I
10.1080/14660820410021311
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We reviewed retrospectively 793 consecutive patients discharged with ALS diagnosis between 1971 and 1998 to identify survival predictors. Vital status in July 2001 was known for all patients. Mean age at onset was 56 (SD 11.7) years and mean age at diagnosis was 57.4 (SD 11.5) years. Onset symptoms were bulbar in 20.8% of patients. The median survival time from symptoms onset was 2.9 years (95% CI 2.7-3.1). Survival from onset was 93% after one, 48% after three and 24% after five years. Median survival was shorter in patients with time between onset and diagnosis <12 months than in those diagnosed >3 months; (2.1 years vs. 5.9 years; P<0.001). Patients with onset after age 65 had a 4.2 times greater risk of death than patients less than 40 years. Bulbar onset was associated with 1.4 times greater risk of death than spinal onset. Patients diagnosed after 1990 had longer median survival (3.3 years) than those diagnosed in 1971-1979 (2.4 years) (P<0.001). As expected, age, bulbar onset and short time from onset to diagnosis were independent predictors of survival. We also found a significant increase in survival over time, probably due to improved comprehensive treatment of ALS patients in Italy.
引用
收藏
页码:208 / 212
页数:5
相关论文
共 36 条
[1]  
Aboussouan LS, 2001, MUSCLE NERVE, V24, P403, DOI 10.1002/1097-4598(200103)24:3<403::AID-MUS1013>3.0.CO
[2]  
2-3
[3]  
[Anonymous], 1993, INT CLASS DIS
[4]   Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials [J].
Armon, C ;
Moses, D .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 160 :S37-S41
[5]   A randomized controlled trial of recombinant interferon beta-1a in ALS [J].
Beghi, E ;
Chiò, A ;
Inghilleri, M ;
Mazzini, L ;
Micheli, A ;
Mora, G ;
Poloni, M ;
Riva, R ;
Serlenga, L ;
Testa, D ;
Tonali, P .
NEUROLOGY, 2000, 54 (02) :469-474
[6]   El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis [J].
Brooks, BR ;
Miller, RG ;
Swash, M ;
Munsat, TL .
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2000, 1 (05) :293-299
[7]   THE PROGNOSIS OF ADULT-ONSET MOTOR-NEURON DISEASE - A PROSPECTIVE-STUDY BASED ON THE SCOTTISH MOTOR-NEURON DISEASE REGISTER [J].
CHANCELLOR, AM ;
SLATTERY, JM ;
FRASER, H ;
SWINGLER, RJ ;
HOLLOWAY, SM ;
WARLOW, CP .
JOURNAL OF NEUROLOGY, 1993, 240 (06) :339-346
[8]   Early symptom progression rate is related to ALS outcome -: A prospective population-based study [J].
Chiò, A ;
Mora, G ;
Leone, M ;
Mazzini, L ;
Cocito, D ;
Giordana, MT ;
Bottacchi, E ;
Mutani, R .
NEUROLOGY, 2002, 59 (01) :99-103
[9]   Amyotrophic lateral sclerosis care in Italy:: a nationwide study in neurological centers [J].
Chiò, A ;
Silani, V .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 191 (1-2) :145-150
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187